Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
NCT01446731
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Prostatic Neoplasms
Interventions
BIOLOGICAL:
mRNA transfected dendritic cell
DRUG:
Docetaxel
Sponsor
Inge Marie Svane